2022
DOI: 10.1016/j.matpr.2022.05.354
|View full text |Cite
|
Sign up to set email alerts
|

Synthesis, characterization of ruthenium (III) macrocyclic complexes of 1,4,8,11-tetraazacyclotetradecane(cyclam) and in vitro assessment of anti-cancer activity

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1

Citation Types

0
3
0

Year Published

2022
2022
2024
2024

Publication Types

Select...
7

Relationship

0
7

Authors

Journals

citations
Cited by 9 publications
(3 citation statements)
references
References 49 publications
0
3
0
Order By: Relevance
“…A Ru(III) complex with 1,4,8,11-tetraazacyclotetradecane exhibited an antiproliferative effect against SiHa cells, with an IC 50 of 48 μM after 48 h of exposure [ 77 ]. Cell morphology changes were observed, such as nuclear fragmentation.…”
Section: Novel Metal Complexes In Cancer Therapymentioning
confidence: 99%
“…A Ru(III) complex with 1,4,8,11-tetraazacyclotetradecane exhibited an antiproliferative effect against SiHa cells, with an IC 50 of 48 μM after 48 h of exposure [ 77 ]. Cell morphology changes were observed, such as nuclear fragmentation.…”
Section: Novel Metal Complexes In Cancer Therapymentioning
confidence: 99%
“…Therefore, researchers are seeking better ways to eliminate cancer cells, with less side effects. Some researchers are working on the use of various macrocyclic ligands for cancer therapy, making ruthenium an ideal choice over other transition metals due to its special chemical properties[ 4 ]. However, what plagues most cancer treatments is the presence of a small number of cancer stem cells (CSCs) in tumor tissues[ 5 , 6 ], which have the potential for self-renewal, unlimited proliferative capacity, and multidirectional differentiation[ 5 , 7 ].…”
Section: Introductionmentioning
confidence: 99%
“…With increasing concentration of drug the viability of cells, were decreased. Authors demonstrated that complex exhibited significant anticancer attribute in the pathogenesis of cervical cancer [ 37 ].
Fig.
…”
Section: Introductionmentioning
confidence: 99%